Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis

FEBS Lett. 1993 Jul 12;326(1-3):56-8. doi: 10.1016/0014-5793(93)81760-w.

Abstract

Encapsulation of amphotericin B in tuftsin-bearing liposomes greatly increased its efficacy in treatment of human aspergillosis in mice. Also, the drug efficacy was significantly increased by pretreating the animals with drug-free tuftsin-bearing liposomes. These results demonstrate that macrophage activation can considerably enhance the therapeutic efficacy of antifungal drugs, like amphotericin B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amphotericin B / administration & dosage*
  • Amphotericin B / therapeutic use
  • Animals
  • Aspergillosis / drug therapy*
  • Aspergillus fumigatus*
  • Drug Carriers
  • Humans
  • Liposomes
  • Macrophage Activation
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Tuftsin / administration & dosage*
  • Tuftsin / therapeutic use

Substances

  • Drug Carriers
  • Liposomes
  • Amphotericin B
  • Tuftsin